The teplizumab injection binds to certain immune system cells and delays progression to type 1 diabetes. Teplizumab may deactivate the immune cells that attack insulin-producing cells, while increasing the proportion of cells that help moderate the immune response. Teplizumab is administered by injection once daily for 14 consecutive days.
In tests teplizumab’s safety and efficacy were evaluated in a randomized, double-blind, event-driven, placebo-controlled trial with 76 patients in the developing stages of type 1 diabetes.
Teplizumab is under review in the UK, but it has not yet been approved. However, the approval in the US could begin the process for this life-changing treatment to be made available to people at high risk of type 1 diabetes in the UK at a later date.
Find out more about type 1 diabetes
Support DRWF by making a donation here
Find out more about DRWF-funded research here
Find out more about DRWF fundraising here
To receive the charity’s latest bulletins as they become available, please sign up here
Read DRWF diabetes information leaflets here
Join the Diabetes Wellness Network here
I would like to make a regular donation of
I would like to make a single donation of